Interleukin 1α and interleukin 18 in patients with vitiligo – Results of a case-control study

Vitiligo is a depigmenting disorder resulting from loss of functional melanocytes in the skin. Variety of inflammatory mediators participate in the regulation of melanogenesis in melanocytes: interleukin-18 (IL-18), interleukin-33, granulocyte-macrophage colony stimulating factor, interferon-γ, prostaglandin E2 have the effect of promoting melanogenesis, while interleukin-1 (IL-1), interleukin-4, interleukin-6, interleukin-17 and tumor necrosis factor can inhibit melanogenesis.Evaluation of IL-1α and IL-18 levels in peripheral blood in patients with vitiligo compared to healthy controls.Fifty patients aged 18-81 with vitiligo participated in the study. The control group consisted of 38 healthy people. Venous blood samples were obtained from each participant. Serum IL-1α and IL-18 concentrations were determined using the enzyme-linked immunoabsorbent assay (ELISA).Among patients with vitiligo, the mean concentration of IL-1α was 0.13 (± 0.535) pg/mL, while in the control group it was 0.51 (± 1.51). There were no statistically significant differences in IL-1α concentrations between patients in the study group compared to the control group (p > 0.05). In the study group, the mean IL-18 concentration was 141.05 (± 136.33) pg/mL vs 137.33 (± 105.83) pg/mL in the controls. There were no statistically significant differences in IL-18 concentrations between patients in the study group compared to the controls (p > 0.05). In the Spearman correlation test, no correlation was confirmed between IL1α and IL-18 concentrations in the group of patients with vitiligo vs healthy people.There is no correlation between Il-1 and Il-18 concentration in the blood sera of patients with vitiligo.